Effect of a Hypocretin/Orexin Antagonist on Neurocognitive Performance
Abstract
In Year 5, we completed study enrollment. In total, 203 participants received the study intervention. Safety reports were sent to the study drug sponsor Actelion on a monthly basis. Both blinded and unblinded monitoring visits of study procedures and facilities are ongoing and should be completed by the end of October 2014. We are currently working on data cleaning, quality control efforts, and edit checks and hope to begin analyses in November 2014.
Document Details
- Document Type
- Technical Report
- Publication Date
- Sep 01, 2014
- Accession Number
- ADA610837
Entities
People
- Thomas Neylan
Organizations
- Northern California Institute for Research and Education